Zobrazeno 1 - 10
of 98
pro vyhledávání: '"E Achille"'
Autor:
L Mineur, E François, C Plassot, J M Phelip, L Miglianico, L M Dourthe, N Bonichon, L Moreau, R Guimbaud, D Smith, E Achille, R Hervé, J M Bons, S Remy, R Faroux, A L Villing, A Mahamat, I Rabbia, P Soulié, I Baumgaertner, N Mathé, L Vazquez, R Boustany
Publikováno v:
PLoS ONE, Vol 15, Iss 12, p e0243997 (2020)
BackgroundCetuximab improves progression-free survival (PFS) and overall survival (OS) in patients with KRAS wild type (wt) metastatic colorectal cancer (mCRC). Few data are available on factors impacting both efficacy and compliance to cetuximab tre
Externí odkaz:
https://doaj.org/article/19e961212abf44a098451fcf052dcba4
Autor:
William Burnett, Nelli Klinova McMillan, Anne E. D'Achille, Jeffery L. Coffer, Bach Pham, Jackson Roye, Debora Willinger, Benjamin D. Sherman
Publikováno v:
Solar Energy. 224:984-991
Reported solar conversion efficiencies of aqueous dye-sensitized solar cells (DSSCs) trail those of traditional organic electrolyte-based systems but offer the potential for lower environmental impact and overall cost. Methods for improving the photo
Autor:
Brice Sinsin, E. Achille Assogbadjo, Rodrigue Idohou, Fortuné Azihou, T. Jean-Didier Akpona, S. Donalde Dolorès M. Deguenon
Publikováno v:
European Scientific Journal ESJ. 17
The sustainable conservation of forest resources in a context of climate change and population growth would be compromised in their current form of exploitation by rural communities. The objective of this study is to assess the impact of climate chan
Publikováno v:
Nanoscale advances. 3(12)
Europium-doped CeO2 nanomaterials have been investigated for a variety of sensing and biological applications, as doping enhances the catalytic activity of CeO2 and contributes visible fluorescence to the nanomaterial. However, scant evidence is avai
Autor:
Roberto Gonzalez-Rodriguez, Anton V. Naumov, Elizabeth Campbell, Anne E. D'Achille, Bong Han Lee, Jeffery L. Coffer
Publikováno v:
ACS biomaterials scienceengineering. 6(12)
Near-infrared (NIR) fluorescence provides a new avenue for biomedical fluorescence imaging that allows for the tracking of fluorophore through several centimeters of biological tissue. However, such fluorophores are rare and, due to accumulation-deri
Autor:
A. Abakar Mahamat, N. Mathé, Roger Faroux, R. Boustany, P. Soulié, L. Moreau, Isabelle Baumgaertner, R. Hervé, J. M. Phelip, D. Smith, J. M. Bons, L. Vazquez, Laurent Miglianico, Eric Francois, Rosine Guimbaud, Laurent Mineur, Louis-Marie Dourthe, A. L. Villing, S. Remy, E. Achille, N. Bonichon, Carine Plassot, I. Rabbia
Publikováno v:
PLoS ONE
PLoS ONE, Vol 15, Iss 12, p e0243997 (2020)
PLoS ONE, Vol 15, Iss 12, p e0243997 (2020)
Background Cetuximab improves progression-free survival (PFS) and overall survival (OS) in patients with KRAS wild type (wt) metastatic colorectal cancer (mCRC). Few data are available on factors impacting both efficacy and compliance to cetuximab tr
Autor:
Xavier Pivot, Gilles Romieu, Marc Debled, Jean-Yves Pierga, Pierre Kerbrat, Thomas Bachelot, Alain Lortholary, Marc Espié, Pierre Fumoleau, Daniel Serin, Jean-Philippe Jacquin, Christelle Jouannaud, Maria Rios, Sophie Abadie-Lacourtoisie, Laurence Venat-Bouvet, Laurent Cany, Stéphanie Catala, David Khayat, Laetitia Gambotti, Iris Pauporté, Celine Faure-Mercier, Sophie Paget-Bailly, Julie Henriques, Jean Marie Grouin, C Piprot, L Cals, L Chaigneau, F Demarchi, T N'Guyen, U Stein, C Villanueva, JL Bréau, AK Chouahnia, P Saintigny, F Boué, P deSaint-Hilaire, I Guimont, N Grossat, B Valenza, E Lévy, J Médioni, C Delbaldo, J Grenier, D Pouessel, S Lavau-Denès, C Falandry, C Fournel-Fédérico, G Freyer, S Tartas, V Trillet-Lenoir, F Bons, G Auclerc, S Chièze, N Raban, C Tournigand, S Trager-Maury, G Bousquet, C Cuvier, S Giacchetti, A Hocini, C LeMaignan, JL Misset, D Avenin, C Beerblock, J Gligorov, P Rivera, H Roché, P Bougnoux, N Hajjaji, O Capitain, R Delva, P Maillart, P Soulié, H Bonnefoi, M Durand, N Madranges, L Mauriac, P Chollet, AF Dillies, X Durando, JP Ferrière, C Mouret-Reynier, JM Nabholtz, I Van Praagh, P Cottu, V Diéras, A Durieux, M Galotte, V Girre, S Henry, I Iurisci, M Jouve, V Laurence, L Mignot, S Piperno-Neumann, P Tresca, B Coudert, E Ferrant, F Mayer, AC Vanneuville, J Bonneterre, V Servent, L Vanlemmens, P Vennin, JP Guastalla, P Biron, L Dupuy-Brousseau, L Lancry, I Ray-Coquard, P Rebattu, O Trédan, JM Extra, F Rousseau, C Tarpin, M Fabbro, E Luporsi, L Uwer, B Weber, D Berton-Rigaud, E Bourbouloux, M Campone, JM Ferrero, P Follana, R Largillier, V Mari, B Costa, H Curé, JC Eymard, N Jovenin, D Lebrun, J Meunier, G Yazbek, D Gedoin, B Laguerre, C Lefeuvre, E Vauléon, A Chevrier, C Guillemet, M Leheurteur, O Rigal, I Tennevet, C Veyret, E Brain, M Guiterrez, F Mefti-Lacheraf, T Petit, F Dalenc, L Gladieff, F André, S Delaloge, J Domont, J Ezenfis, M Spielmann, P Guillet, V Boulanger, J Provençal, L Stefani, C Alliot, D Ré, C Bellaiche-Miccio, G Boutan-Laroze, R Vanica, P Dion, G Sadki-Benaoudia, A Marti, AL Villing, B Slama, JL Dutel, S Nguyen, R Saad, O Arsène, Z Merad-Boudia, H Orfeuvre, J Egreteau, MJ Goudier, R Lamy, B Leduc, C Sarda, B Salles, C Agostini, I Cauvin, A Dufresne, M Mangold, S Lebouvier-Sadot, B Audhuy, JC Barats, S Cluet-Dennetière, D Zylberait, G Netter, L Gautier-Felizot, I Cojean-Zelek, A Plantade, S Vignot, E Guardiola, P Marti, I deHartingh, R Diab, A Dietmann, S Ruck, C Portois, S Oddou-Lagranière, F Campos-Gazeau, A Bourcier, F Priou, JF Geay, D Mayeur, P Gabez, R ElAmarti, M Combe, P Raichon-Patru, P Amsalhem, J Dauba, D Paraiso, F Guinet, B Duvert, M Litor, F Kara-Slimane, A Bichoffe, N Denizon, P Soyer, F Morvan, S Van-Hulst, L Vincent, C Alleaume, P Ibanez-Martin, A Youssef, Z Tadrist, E Carola, C Pourny, JF Toccanier, N Al-Aukla, K Mahour-Bacha, J Salvat, P Nouyrigat, S Clippe, MC Gouttebel, L Vedrine, G Clavreul, O Collard, D Mille, Y Goubely, R Hervé, S Kirscher, F Plat, V Delecroix, V Ligeza-Poisson, D Coeffic, D Fric, C Garnier, C Leyronnas, T Kreitman, E Teissier, P Martin, S Rohart deCordoue, C ElKouri, JF Ramée, C Laporte, O Bernard, T Altwegg, A Darut-Jouve, JP Dujols, F Darloy, C Giraud, V Pottier-Kyndt, N Achour, S Drony, M Moriceau, C Sarrazin, JC Legueul, J Mandet, D Besson, AC Hardy-Bessard, J Cretin, P Houyau, E Achille, D Genêt, H Thévenot, A Moran-Ribon, JM Pavlovitch, P Ardisson, I Moullet, B Couderc, V Fichet, F Burki, A Auliard, CB Levaché, P Cailleux, F Schaeffer, N Albin, D Sévin-Robiche, J Domas, S Ellis, P Montcuquet, GA Baumont, M Bégue, S Gréget, JL Ratoanina, A Vanoli, C Bielsa, M Bonichon-Lamichhane, D Jaubert, H Laharie-Mineur, L Alcaraz, E Legouffe, H Bourgeois, G Cartron, F Denis, O Dupuis, G Ganem, S Roche-Forestier, L Delzenne, E Chirat, JL Baticle, E Béguier, S Jacquot, E Janssen, H Lauché, A LeRol, JP Chantelard, GA L'Helgoualc'h, EC Antoine, A Kanoui, JF Llory, JM Vannetzel, J Vignoud, C Bruna, T Facchini, K Moutel-Corviole, A Voloch, A Ghoul, D Loiseau, N Barbet, N Dohollou, K Yakendji
Publikováno v:
Lancet (London, England). 393(10191)
Summary Background In 2013, the interim analysis of the Protocol for Herceptin as Adjuvant therapy with Reduced Exposure (PHARE) trial could not show that 6 months of adjuvant trastuzumab was non-inferior to 12 months. Here, we report the planned fin
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.